BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 21/01/2026

FDA Announces Draft Guidance for Industry on Minimal Residual Disease and Complete Response in Multiple Myeloma

The FDA is announcing the availability of a draft guidance for industry on using minimal residual disease (MRD) and complete response (CR) as endpoints to support accelerated approval for multiple myeloma treatments.

Source: Federal Register — Food and Drug AdministrationOpen original release →